
A retrospective study was conducted of the clinical records of 41 patients discharged from a hospital in Tarapoto, Peru, between August 1992 and June 1996 following treatment for Plasmodium falciparum malaria. Patients ranged in age from 18 to 65 years; 25 were male. The cases were uniformly distributed throughout the year. The duration of illness averaged 11 days. At admission, 40 patients had fever, 36 had shaking chills, 29 had headache, 21 had nausea and vomiting, 21 had hyporexia, 15 had pallor, and 13 had splenomegaly. 3 of the 16 women were pregnant. 7 patients reported a history of malaria. The admission diagnosis was malaria in 33 cases. 31 patients were treated with chloroquine; 18 were subsequently treated with pyrimethamine-sulfadoxin and 1 received doxycycline. No cases of grave illness or death occurred. The increasing presence of Plasmodium falciparum malaria in the Peruvian lowlands should promote review of the adequacy of control programs.
Primary resistance to anti-tuberculosis (TB) drugs refers to resistance in a patient not previously treated, while acquired or secondary resistance occurs in patients completing several months of treatment or treated in the past. Primary resistance usually involves one drug, most often streptomycin, while secondary resistance usually involves two or more. The Chilean TB control program has used a single standardized regime for initial treatment based on four drugs since the advent of short-duration chemotherapy in the early 1980s. 61.4% of patients treated for TB in 1991 who had positive sputum tests after 4 months were found to be resistant, and 36% were multiresistant. Among those previously treated, the rate of resistance was 22%, and only 3.7% showed multiple resistance. Because of the difference in rates of resistance, the two groups should be treated separately. A controlled study of 1970 TB patients in metropolitan Santiago treated with short-duration therapy with at least 18 months of follow-up between 1978 and 1985 showed that the type of resistance was closely related to the risk of treatment failure. The close relation allows the use of data on primary and acquired resistance to project, in a specific community, the proportion of TB incidence that will be associated with treatment failure attributable to drug resistance.
OBJECTIVE:To carry out a prospective study on 1,569 females to evaluate the diagnostic utility of adding buffered Wright solution to Papanicolaou stain for observing cytoplasmic inclusions in cervicovaginal cytology. STUDY DESIGN:Group A had multivacuolated cells and group B, granules (not in a vacuole) in the cytoplasm of low-intermediate epithelial or parabasal cells. There were 7 patients in group A and 16 in group B. Two duplicate plates of cervicovaginal secretions were obtained from each patient before and after treatment; one was stained with Papanicolaou stain and the other with our variant. The trial of therapy consisted of doxycycline (effectiveness for statistical analysis = 0.9) in oral doses of 100 mg every 12 hours for 7 days; 7 days after the beginning of treatment, check samples were obtained. RESULTS:In group A, six patients had cytoplasmic inclusions with the variant stain, and two had cytoplasmic inclusions with Papanicolaou stain. The binomial test revealed that probably six of the seven patients had infections with Chlamydia (P = .372) and that in 100% of cases, the variant stain showed cytoplasmic inclusions, while Papanicolaou stain was observed in 33% of cases. These findings were morphologically and statistically proven (P = .124) on control slides with posttreatment absence of multivacuolated cells. CONCLUSION:In relation to the selection criteria for B group, the intracytoplasmic granules found in parabasal and low intermediate cells had no relation to Chlamydia. The study demonstrated the superiority of our variant of Papanicolaou stain for cervicovaginal Chlamydia diagnosis.